Universal Ibogaine Inc. (IBOGF)
USD 0.02
(0.0%)
USD 0.02
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 6.31 Million CAD | 58.27% |
| 2021 | 3.99 Million CAD | 3323.04% |
| 2020 | 116.61 Thousand CAD | -46.31% |
| 2019 | 217.2 Thousand CAD | -32.26% |
| 2018 | 320.66 Thousand CAD | -20.94% |
| 2017 | 405.6 Thousand CAD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q2 | 6 Million CAD | -3.77% |
| 2023 Q1 | 6.23 Million CAD | -1.27% |
| 2023 Q3 | 5.87 Million CAD | -2.12% |
| 2022 FY | 6.31 Million CAD | 58.27% |
| 2022 Q1 | 13.04 Million CAD | 155.41% |
| 2022 Q4 | 6.31 Million CAD | -39.06% |
| 2022 Q3 | 10.36 Million CAD | 0.0% |
| 2021 Q1 | 119.58 Thousand CAD | -25.64% |
| 2021 FY | 3.99 Million CAD | 3323.04% |
| 2021 Q4 | 5.1 Million CAD | 132.36% |
| 2021 Q3 | 2.19 Million CAD | 2922.73% |
| 2021 Q2 | 72.74 Thousand CAD | -39.17% |
| 2020 Q2 | 137.24 Thousand CAD | -23.54% |
| 2020 Q1 | 179.49 Thousand CAD | -13.37% |
| 2020 FY | 116.61 Thousand CAD | -46.31% |
| 2020 Q4 | 160.82 Thousand CAD | 37.91% |
| 2020 Q3 | 116.61 Thousand CAD | -15.03% |
| 2019 Q3 | 217.2 Thousand CAD | -9.82% |
| 2019 FY | 217.2 Thousand CAD | -32.26% |
| 2019 Q1 | 257.8 Thousand CAD | -11.38% |
| 2019 Q2 | 240.85 Thousand CAD | -6.58% |
| 2019 Q4 | 207.19 Thousand CAD | -4.61% |
| 2018 Q4 | 290.92 Thousand CAD | -9.27% |
| 2018 Q1 | 493.06 Thousand CAD | -22.25% |
| 2018 FY | 320.66 Thousand CAD | -20.94% |
| 2018 Q3 | 320.66 Thousand CAD | 0.0% |
| 2017 FY | 405.6 Thousand CAD | 0.0% |
| 2017 Q4 | 634.18 Thousand CAD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioxytran, Inc. | 137.63 Thousand USD | -4490.022% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 83.737% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -8174.111% |
| SQZ Biotechnologies Company | 107.18 Million USD | 94.106% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -341.164% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 40.14% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 95.148% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -8630.208% |
| Marizyme, Inc. | 22.01 Million USD | 71.303% |
| Genus plc | 1.02 Billion USD | 99.386% |
| Pharming Group N.V. | 462.85 Million USD | 98.635% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -90.691% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -1165.956% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -907.594% |
| ContraFect Corporation | 20.67 Million USD | 69.449% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -1553.06% |
| IMV Inc. | 31.33 Million USD | 79.838% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -52.378% |
| ONE Bio Corp. | 70.08 Million USD | 90.986% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 95.084% |
| Mesoblast Limited | 667.9 Million USD | 99.054% |
| MultiCell Technologies, Inc. | 126.22 USD | -5005140.849% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 82.042% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.813% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -719.784% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -2317.976% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 12.496% |
| Biomind Labs Inc. | 73.81 Thousand USD | -8458.251% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -336.046% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 78.952% |
| Skye Bioscience, Inc. | 11.94 Million USD | 47.09% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -365.094% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -130.038% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -1518.382% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -222.625% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -818.945% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -572.309% |
| EV Biologics, Inc. | 431.71 Thousand USD | -1363.38% |
| Q BioMed Inc. | 3.51 Million USD | -79.707% |
| GB Sciences, Inc. | 103.44 Thousand USD | -6007.398% |
| Alpha Cognition Inc. | 2.45 Million USD | -157.634% |
| CSL Limited | 38.02 Billion USD | 99.983% |
| Agentix Corp. | 261.39 Thousand USD | -2316.912% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 98.584% |
| Enzolytics Inc. | 361.7 Million USD | 98.253% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 8.11 Million USD | 22.149% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -236.423% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -142.687% |
| argenx SE | 4.54 Billion USD | 99.861% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 77.392% |
| HST Global, Inc. | 1526.00 USD | -413898.362% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 86.756% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -539.456% |
| Halberd Corporation | 10.13 Thousand USD | -62259.244% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -887.658% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 29.405% |
| Zenith Capital Corp. | 7410.00 USD | -85157.962% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -27631.948% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -1863.175% |
| AVAX Technologies, Inc. | 7.37 Million USD | 14.362% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -2317.171% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -580.806% |
| Ember Therapeutics, Inc. | 184.00 USD | -3433386.413% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -10049.105% |
| Helix BioMedix, Inc. | 3.02 Million USD | -108.841% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 88.012% |
| Kadimastem Ltd | 2.3 Million USD | -174.193% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | 56.611% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -10965.287% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -273389.827% |
| LadRx Corporation | 2.3 Million USD | -173.741% |
| Cell Source, Inc. | 195.17 Thousand USD | -3136.964% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -1214.644% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1686.57% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -1686.57% |
| Affymax, Inc. | 7.44 Million USD | 15.12% |
| Mobile Lads Corp. | 52.00 USD | -12149159.615% |
| Itoco Inc. | 1.4 Million USD | -351.235% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -6504.446% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -5860.014% |
| International Stem Cell Corporation | 5.39 Million USD | -17.21% |
| CytoDyn Inc. | 11.13 Million USD | 43.269% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -4318.778% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -35233.417% |
| Qrons Inc. | 420.00 USD | -1504094.048% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -1538.934% |
| SYBLEU INC | 330.46 Thousand USD | -1811.718% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -1044.247% |
| Rebus Holdings, Inc. | 5000.00 USD | -126252.3% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -1443.057% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 57.888% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 61.894% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -7896.981% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -630.633% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 15.956% |
| Neutra Corp. | 2851.00 USD | -221492.95% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 80.505% |
| PureTech Health plc | 693.97 Million USD | 99.09% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 21.725% |
| IXICO plc | 15.84 Million USD | 60.126% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 23.719% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 93.886% |
| CSL Limited | 38.02 Billion USD | 99.983% |
| Cellectis S.A. | 333.99 Million USD | 98.108% |